PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Protagonist Therapeutics, Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$134.44+5.69 (+4.42%)
Close on Oct 19, 2026
- Market cap
- $9.55B
- P/E (TTM)
- 130.5
- Dividend yield
- –
Dividends
Protagonist Therapeutics has not reported a dividend
No dividend per share appears in Protagonist Therapeutics's annual filings since fiscal 2013.